Lauren Antrim, MD, of City of Hope Cancer Center Duarte, emphasized the need for more evidence to guide optimal immunotherapy duration and sequencing in in non–small cell lung cancer (NSCLC), highlighting ongoing trials and the potential role of ctDNA in tailoring treatment strategies.